Article By:
KKD Healthcare Analytics
Friday, September 1, 2017 11:46 AM EDT
Immune Design announced interim top line data from a Phase 2 clinical trial assessing the combination of its CMB305 and Roche's Tecentriq (atezolizumab) compared to Tecentriq alone in 88 soft tissue sarcoma patients.